首荟通便胶囊抗幽门螺杆菌活性及机制的网络药理学研究
本研究采用HPLC、UHPLC-MS/MS和网络药理学识别首荟通便胶囊(SHTB)的活性成分及抗幽门螺杆菌(H. pylori)靶点,并通过体外实验验证其抗菌活性与机制。结果显示SHTB对敏感及耐药H. pylori菌株的MIC为160–320 μg/mL,MBC为MIC的2倍,与克拉霉素、甲硝唑、左氧氟沙星或阿莫西林联用无拮抗作用,且通过抑制PI3K/AKT、MAPK和NF-κB通路减轻感染损伤。
要点
- SHTB对敏感及耐药H. pylori菌株的MIC为160–320 μg/mL,MBC为MIC的2倍。
- SHTB与克拉霉素、甲硝唑、左氧氟沙星或阿莫西林联用未见拮抗效应。
- SHTB通过抑制PI3K/AKT、MAPK和NF-κB通路减轻H. pylori感染损伤。
核心结论
- SHTB在体外具有抗H. pylori活性,并通过调控PI3K/AKT、MAPK和NF-κB信号通路网络发挥保护作用。
研究设计与样本
- 采用HPLC、UHPLC-MS/MS和网络药理学识别SHTB活性成分及抗H. pylori靶点,并用肉汤稀释法测定抗菌活性。
- 机制研究采用电子显微镜观察、免疫荧光染色、RT-qPCR和Western blotting等技术。
主要发现
- 在SHTB中鉴定出42种化合物,数据库筛选获得365个与SHTB成分相关的靶基因和1035个与H. pylori感染相关的基因。
- SHTB对敏感及耐药H. pylori菌株的MIC范围为160–320 μg/mL,MBC为MIC的2倍。
- SHTB与克拉霉素、甲硝唑、左氧氟沙星或阿莫西林联用未观察到拮抗效应。
- SHTB破坏H. pylori形态、降低尿素酶活性并下调毒力相关基因表达,同时增强宿主细胞抗黏附能力。
- SHTB通过抑制PI3K/AKT、MAPK和NF-κB信号通路的异常激活减轻H. pylori感染诱导的损伤。
关键数值与推荐
- SHTB对敏感及耐药H. pylori菌株的MIC为160–320 μg/mL,MBC为MIC的2倍。
- SHTB与克拉霉素、甲硝唑、左氧氟沙星或阿莫西林联用无拮抗作用。
临床怎么用
- SHTB在体外对敏感及耐药H. pylori菌株均有抑菌活性,且与常用抗菌药物联用无拮抗,但临床应用于H. pylori感染仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Shouhui Tongbian capsule (SHTB), a commercial Chinese patent medicine, has been shown to modulate gut microbiota dysbiosis and contains antibacterial active ingredients against Helicobacter pylori (H. pylori). H. pylori is a Gram-negative bacterium that colonizes the gastric mucosal and disrupt gastrointestinal microbiota balances. However, the precise mechanism underlying the anti-H. pylori effects of SHTB remains unclear. AIM OF THE STUDY: To investigate the in vitro anti-H. pylori effects and underlying mechanisms of SHTB. MATERIALS AND METHODS: High-performance liquid chromatography (HPLC), ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), and network pharmacology analyses were used to identify the active compounds and potential targets of SHTB associated with H. pylori infection. The anti-H. pylori activity of SHTB was determined using the broth dilution method. Mechanistic studies were conducted through techniques such as electron microscopy observation, immunofluorescence staining, real-time quantitative polymerase chain reaction (RT-qPCR), and Western blotting analyses. RESULTS: A total of 42 compounds were identified in SHTB. Database screening yielded 365 target genes related to SHTB constituents and 1035 genes associated with H. pylori infection. In vitro assays demonstrated that the minimum inhibitory concentration (MIC) of SHTB against both susceptible and resistant H. pylori strains ranged from 160 to 320 μg/mL, with the minimum bactericidal concentration (MBC) being twice the MIC. No antagonistic effects were observed when SHTB was combined with clarithromycin, metronidazole, levofloxacin, or amoxicillin. SHTB disrupted H. pylori morphology, reduced urease activity, and downregulated virulence-associated gene expression. Cellular assay further indicated that SHTB enhanced the anti-adhesion capability of host cells. Furthermore, SHTB alleviated H. pylori infection-induced damage by inhibiting the abnormal activation of the PI3K/AKT, MAPK, and NF-κB signaling pathway. CONCLUSIONS: These findings provide a theoretical basis for elucidating the mechanism of SHTB against H. pylori infection and confirm its protective role in combating H. pylori infection through the regulation of the PI3K/AKT, MAPK, and NF-κB signaling pathway network.
引用
- Zhang T, Li H, Hao Y, et al. Exploring the anti-Helicobacter pylori activity and mechanism of Shouhui Tongbian through chemical composition analysis and network pharmacology. J Ethnopharmacol. 2025. PMID: 41205636. doi:10.1016/j.jep.2025.120869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。